Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. [electronic resource]
Producer: 20110509Description: 1014-21 p. digitalISSN:- 1527-7755
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- chemistry
- Chemotherapy, Adjuvant
- Chi-Square Distribution
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Drug Administration Schedule
- Female
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Logistic Models
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Odds Ratio
- Paclitaxel -- administration & dosage
- Proportional Hazards Models
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
- United States
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.